1 / 19

Intermediate Risk TAVR 1 Year Later

Intermediate Risk TAVR 1 Year Later. Stephen Bailey, MD Director, Division of Cardiac Surgery Allegheny General Hospital September 27, 2017. Disclosure.

mmaki
Download Presentation

Intermediate Risk TAVR 1 Year Later

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Intermediate Risk TAVR1 Year Later Stephen Bailey, MD Director, Division of Cardiac Surgery Allegheny General Hospital September 27, 2017

  2. Disclosure • The information provided is the experience of the Allegheny General Hospital, and Edwards Lifesciences has not independently evaluated these data. Outcomes are dependent upon a number of facility and surgeon factors which are outside Edwards’ control. These data should not be considered promises or guarantees by Edwards that the outcomes presented here will be achieved by an individual facility. • Stephen Bailey is a paid consultant to Edwards Lifesciences

  3. AGH

  4. Intermediate RiskOne Year Later • What is the opinion of heart team to IR? • Impact of RCT data • What is the view of referring physicians? • What is the view of patients? • How has IR impacted our program? • What % of IR patients have TAVR? • How have we accommodated growth?

  5. AGH TAVR • Surgical clinic • 3-4 new patients 3-4 mornings/ week • CT/ TTE • 4-5 TAVR every Monday + 2 Fridays/month

  6. AGH OHS Volume

  7. AGH OHS Volume

  8. TAVR Access

  9. DRG Breakdown per Year

  10. Trend of Average STS scores

  11. Impact of Intermediate risk

  12. Impact of Intermediate Risk on Length of Stay

  13. TAVR Complications (In-Hospital)

  14. TAVR Anesthesia

  15. ICU Hours

  16. Intermediate RiskOne Year Later • What is the opinion of heart team to IR? • Impact of RCT data • What is the view of referring physicians? • What is the view of patients? • How has IR impacted our program? • What % of IR patients have TAVR? • How have we accommodated growth?

  17. Summary • Intermediate risk came during ongoing evolution of evaluation and treatment protocols • Overall risk profile of our patients trending slowly down (never knew there were so many 90 year olds) • Program/ pathway refinement dovetailed nicely with IR approval to enhance financial performance

  18. Thank you

  19. Please see important safety information at the speaker’s podium Edwards and Edwards Lifesciences are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. PP--US-2342 v1.0

More Related